Notice: Users may be experiencing issues with displaying some pages on stanfordhealthcare.org. We are working closely with our technical teams to resolve the issue as quickly as possible. Thank you for your patience.
Learn about the flu shot, COVID-19 vaccine, and our masking policy »
New to MyHealth?
Manage Your Care From Anywhere.
Access your health information from any device with MyHealth. You can message your clinic, view lab results, schedule an appointment, and pay your bill.
ALREADY HAVE AN ACCESS CODE?
DON'T HAVE AN ACCESS CODE?
NEED MORE DETAILS?
MyHealth for Mobile
Get the iPhone MyHealth app »
Get the Android MyHealth app »
Multicenter trial of everolimus in pediatric renal transplant recipients: Results at three year PEDIATRIC TRANSPLANTATION Ettenger, R., Hoyer, P., Grimm, P., Webb, N., Loirat, C., Mahan, J. D., Mentser, M., Niaudet, P., Offner, G., Vandamme-Lombaerts, R., Hexham, J. M. 2008; 12 (4): 456-463
Abstract
There are few prospective clinical trials of mTOR inhibitors (or proliferation signal inhibitors) combined with CNI inhibitors in de novo pediatric renal transplantation. Results reported here are from a multicenter, open-label study in de novo pediatric renal transplant patients (
View details for DOI 10.1111/j.1399-3046.2007.00832.x
View details for Web of Science ID 000255551700015
View details for PubMedID 18466433